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ABSTRACT 
Objective: Fatty acid biosynthesis is essential for bacterial survival. Components of this biosynthetic pathway have been identified as attractive 
targets for the development of new antibacterial agents. β–Ketoacyl acyl carrier protein synthase (KAS) II is a key catalyst in bacterial fatty acid 
biosynthesis. It is related to control the temperature dependent regulation of fatty acid composition. 
Methods: Structure of KasII (FabF) was retrieved from the Protein Data Bank and the structures of flavonoid compounds have been collected from 
zinc database. Molecular docking and drug likeness studies were performed for those natural compounds to evaluate and analyze the anti-
antimicrobial activity. 
Results: Finally one compound, Casticin binds to KAS II with the most favorable binding energy (-112.5 kcal/mol) whereas the reference (-92.76 
kcal/mol). The fitness score of the compound suggest that this lead can be formulate as an antimicrobial activities drug against gram-negative 
Pseudomonas aeruginosa. 
Conclusions: The results of this study can be implemented in vitro and in vivo in the drug designing pipeline. 
Keywords: Pseudomonas aeruginosa, Fatty acid synthases, KAS II, Docking, Flavonoids, iGEMDOCK. 
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INTRODUCTION 
Pseudomonas aeruginosa is a Gram-negative, aerobic; a non-
fermentative bacterium widely distributed in nature and can survive 
on a wide variety of surfaces and among hospital environment [1]. 
Pseudomonas aeruginosa is a common nosocomial pathogen that 
causes a variety of infections and is an opportunistic human 
pathogen. It is “opportunistic” because it seldom infects healthy 
individuals. Instead, it often colonizes immunocompromised 
patients, like those with cystic fibrosis, cancer or AIDS [2, 3]. The 
most common cause of burn infections is P. aeruginosa. It is such a 
potent pathogen that it attacks up two thirds of the critically ill-
hospitalized patients and this usually portends more invasive 
diseases and acute diseases caused by P. aeruginosa tend to be 
chronic and life-threatening [4]. P. aeruginosa develops resistance by 
various mechanisms like multi-drug resistance efflux pumps, biofilm. 
Formation, production of β-lactamases and aminoglycoside 
modifying enzymes [5,6]. Although several classes of antibacterial 
agents are presently available, resistance in most of the pathogenic 
bacteria to these drugs constantly emerges. In order to prevent this 
serious medical problem, the elaboration of new types of 
antibacterial agents or the expansion of bioactivity of the previous 
drugs is a very important task [7]. Therefore, in recent years, the 
research has been focused toward development of new antibacterial 
agents, which may act through novel target, overcoming the problem 
of acquired resistance. 
A promising target is the fatty acid synthase (FAS) pathway in 
bacteria. Fatty acid biosynthesis (FAB) is an essential metabolic 
process of prokaryotic organisms and is required for cell viability 
and growth [8]. Large multifunctional proteins termed type I fatty 
acid synthases (FAS I) catalyze these essential reactions to 
eukaryotes [9, 10]. In contrast, bacteria use multiple enzymes to 
accomplish the same goal and are referred to as type II, or 
dissociated, fatty acid synthases (FAS II) [11]. The type II system has 
been most extensively studied in Pseudomonas aeruginosa [12, 13]. 
The β-ketoacyl carrier protein synthases (β-KAS) are key regulators 
of fatty acid biosynthesis. It is well known that three types of β-
ketoacyl acyl carrier protein synthase (KAS) enzymes, KAS I (FabB, 
β-ketoacyl–ACP synthase I), KAS II (FabF, β-ketoacyl–ACP synthase 
II), and KAS III (FabH, β-ketoacyl–ACP synthase III).  
The β-Ketoacyl-Acyl Carrier Protein Synthase I (KAS I) play a very 
important role in the elongation of fatty acids. Studies have shown 
that mutants lacking the KAS I enzymes face serious problems in 
growth and require exogenous unsaturated fatty acids. The function 
of KAS II is to mainly control the thermal regulation of fatty acid 
composition. Lack of KAS II will result in failure of the elongation of 
palmitoleate to cis vaccinate. However, under standard culture 
conditions, growth is not suppressed. Finally, KAS III is responsible 
for controlling the rate of fatty acid syntheses, by catalyzing the first 
step in the pathway, fig. 1. 
 
 
Fig. 1: The bacterial type II fatty acid biosynthetic pathway [72] 
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These enzymes catalyze the Claisen condensation reaction, 
transferring an acyl primer to malonyl-ACP (Acyl Carrier Protein) 
and thereby creating a β-ketoacyl–ACP that has been lengthened by 
two carbon units [14]. 
Flavonoids are becoming the subject of medical research and they 
have been reported to possess many useful properties, including 
anti-inflammatory, oestrogenic, enzyme inhibition, antimicrobial 
[15, 16], antiallergic, antioxidant [17], vascular and cytotoxic 
antitumour activities. The basic structural feature of flavonoid 
compounds is the 2-phenyl-benzo pyrane or flavane nucleus, which 
consists of two benzene rings (A and B) linked through a 
heterocyclic pyrane ring (C) [18], fig. 2.  
 
 
Fig. 2: The skeleton structure of the flavones (a class of 
flavonoids), with rings named and positions numbered 
 
They can be further classified by their chemical structures that are 
flavones, flavonols, flavanols, flavanones, isoflavones, and 
anthocyanins. The in silico method is used to analyze the target of 
structures of expecting to bind sites, to generate candidate 
molecules, to check for their drug likeness, to dock them with the 
target, to rank them according to their binding energies, and further 
to optimize the molecules for improving binding the features. 
In this work, we computationally predict that flavonoid casticincan 
be used as potential drug candidates against Gram-negative 
Pseudomonas aeruginosa based on that good binding energy toward 
KAS II active sites. 
MATERIALS AND METHODS 
Protein preparation  
The protein, required for the docking studies, has been retrieved 
from the Protein Data Bank (PDB) [19]. The protein has (4JPF) a 
resolution factor of 1.67 Å [19].  
We defined the active site of KAS II based on the x-ray complex 
structure of KAS II protein and 3-benzamido-2-hydroxybenzoic acid 
ligand. The binding sites, which are more flexible, were selected for 
this study. 
Chemical structures were retrieved from ZINC database [20]. The 
MOL2 structural formats of all the 50 components were generated 
from the database ZINC. The set of ligand molecules selected for this 
study was 50 flavonoids compounds from different plant sources 
and which have been selected after an extensive literature survey 
that was performed to hunt for flavonoids that have antimicrobial 
activities via pubmed site [21-26].  
The literature on flavonoids and antimicrobial activities has been 
collected from this database. The flavonoids have aroused 
considerable interest recently because of their potentially beneficial 
effects on human health. They have been reported to have anti-
microbial, anti-allergic, anti-platelet, anti-inflammatory, anti-tumor 
and anti-oxidant activities [27-61] and many flavonoids display low 
toxicity [62] in mammals. In fact, we have selected 50 flavonoids 
without sugars (only the aglycones), as the anti-bacteria effectiveness 
increased when the sugar is separated [62]. Table1 is shown the 
chemical structure of 50 flavonoids with the reference. They were also 
selected in accordance with the Lipinski’s rules of five. 
 
Table 1: The structure of 50 screened flavonoid compounds used in this study 
S. No. Compound ID Chemical name IUPAC Name Compound structure References 
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These phytochemicals were screened in silico for their inhibitory 
activity against the selected enzyme molecules, comparing with 3-
benzamido-2-hydroxybenzoic acid [fig. 3] which is known as 
inhibitor of KAS II. 
 
 
Fig. 3: 3-benzamido-2-hydroxybenzoic acid which is known as 
inhibitor of KAS II 
 
Protein-ligand docking  
In this research, we use iGemdock (iGeneric Evolutionary Method 
Docking) program, which was used in various previous researches 
[63, 64, 65] and it is available for free [66, 67].  
iGemdock v2.1 
Docking software iGemdock was used to dock the protein of the 
enzyme (Kas II) with 50 flavonoids. iGemdock is an integrated 
virtual screening (VS) environment from preparations through post-
screening analysis with pharmacological interactions iGemdock 
provides interactive interfaces to prepare both the binding site of 
the target enzyme and the screening compound library. Each 
compound in the library is then docked into the binding site by using 
the in-house docking tool iGemdock. Subsequently, iGemdock 
generates protein-compound interaction profiles of electrostatic (E), 
hydrogen-bonding (H), and Van der Waal’s (V) interactions. Based 
on these profiles and compound structures, iGemdock infers the 
pharmacological interactions and clusters the screening compounds 
for the post-screening analysis. Finally, iGemdock ranks and 
visualizes the screening compounds by combining the 
pharmacological interactions and energy-based scoring function of 
iGemdock 
Rapid virtual screenings of the 50 ligand compounds were 
performed in the docking tooliGemdock. The docking consisted 
protocol "accurate docking" by setting population size of 800 is set 
with 80 generations and 10 solutions. After the completion of the 
docking, the post docking analysis was performed to find the 
docking pose and its energy values. The empirical scoring function of 
iGemdock was estimated uesing:  
Energy = vdW+Hbond+Elec 
Table 2 illustrates the result of the ten compounds based on the 
most favorable binding energy of flavonoids. 
 
Table 2: The docking binding energy values results using iGEMDOCK 







1 Casticin -112.5 -96.74 -15.76 0 
2 Tangeritin -101.55 -95.72 -5.83 0 
3 Tamarixetin -101.03 -87.03 -14 0 
4 Malvidin -100.92 -90.29 -10.63 0 
5 Isorhamnetin -98.17 -80.35 -17.81 0 
6 Syringetin -97.93 -88.55 -9.38 0 
7 Petunidin -97.65 -85.38 -13.37 0 
8 Tricin -97.32 -83.52 -14.81 0 
9 Fisetin -96.05 -81.88 -14.18 0 
10 Herbacetin -95.54 -81.72 -13.82 0 
11 Benzoic acid, 3-(benzoylamino)-2-
hydroxy 
-92.76 -69.06 -15.38 -3.71 
 
RESULTS AND DISCUSSION 
In silico, docking studies were carried out using iGemdock v2.1. The 
results showed that all the selected flavonoids presented more 
favorable binding energy ranging from-112.5 kcal/mol to-80.9 
kcal/mol when compared to that of the reference (-92.76 kcal/mol). 
Therefore, these molecular docking analyses could lead to further 
development of potent (Kas II) inhibitors for the prevention and 
treatment for diseases caused by Pseudomonas aeruginosa.  
Table II summarizes results of the docking study based on binding 
energies. The energy, representing the best binding energy of 
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inhibitors of this enzyme, was identified by the molecular docking 
procedure. In addition, fig. 4 illustrates the interactions of casticin 
with protein pocket, which has the most favourable binding energy 
and clarify the hydrogen bonding and Van der Waal’s interactions 
with the amino acids.  
 
 
Fig. 4: Predicted docking pose of Casticin lie within the active 
site of the target protein (PDB ID-4JPF). Pink color represents 
the corresponding ligand molecule and green color represents 
the corresponding reference. Green and grey color represents 
the amino acids involved in hydrogen bonding and van der 
Waals interactions respectively 
 
Table 3 shows pharmacological interactions and residues involved in 
the binding site for casticin. Then the pharmacological interactions are 
useful for understanding ligand binding mechanisms of a therapeutic 
target. These interactions are often inferred from a set of active 
compounds that were acquired by experiments. 
 
Table 3: Pharmacological interactions and residues involved in 
the binding site 
PDB ID Predicted pharmacologica 
interactions 
Casticin 











Thegreen and grey color represents the amino acids involved 
in(H)hydrogen bonding and(V) van der Waals are interaction types 
M and S are Main chain and Side chain., In addition, the table 4 
shows distance of hydrogen bond (Å) of some residues in the KAS II 
protein’s active site. 
 
Table 4: The distance of hydrogen bond (Å) of some residues in 
the KAS II protein’s active site 





Post screening analysis  
The performed docking study against the KAS II receptor revealed 
that all flavonoid compounds identified in this study have a superior 
binding energy in comparison to the reference compound 3-
benzamido-2-hydroxybenzoic acid. The analysis identified casticin 
(Zinc-6018556) as having the most favorable binding energy of-
112.5 kcal/mol kcal/mol. Casticin is a methyoxylated flavonol, 
meaning the core flavonoid structure has methyl groups attached. 
Fig. 5 is shown the structure of casticin. 
 
 
Fig. 5: The structure of casticin 
 
The drug-receptor interactions and the fitness score of the 
compound suggest that this lead can be formulate as an 
antimicrobial activities drug against gram-negative Pseudomonas 
aeruginosa. 
Lipinski’s rule of five 
Lipinski et al. formulated the ’Rule of Five’ to relate likelihood of oral 
bioavailability which consists of four important properties (MW, log 
P, number of H bond donors/acceptors), each related to the number 
5. The guidelines are based on data onto the literature for a large 
number of compounds, including all known drugs that correlate 
physical properties with oral bioavailability. The compounds are 
more likely to be membranes permeable and easily absorbed by the 
body if it matches the following criteria:  
1. The molecular weight of less than 500 mg/mol 
2. Has a high lipophilicity (log p less than 5) 
3. Hydrogen bond donors less than 5 
4. Hydrogen bond acceptor is less than 10 
The rule describes molecular properties important for a drug's 
pharmacokinetics in the human body, including their Absorption, 
Distribution, Metabolism, and Excretion ("ADME").  
The rule is important for drug development where a 
pharmacologically active lead structure is optimized step-wise for 
increased activity and selectivity, as well as drug-like properties as 
described by Lipinski's rules [68, 69, 70]. 
Compound classes that are substrates for biological transporters are 
exceptions to the rule. The molecular docking studies and Lipinski’s 
rules facilitate drug development avoiding expensive post clinical 
experiments. 
Veber rule and Molar Refractivity  
1-Veber Rule: In particular, compounds which meet only the two 
criteria of:  
a) 1-rotatable bond count>=10. 
b) 2-polar surface area (PSA) equal to or less than 140 Å. 
Are predicted to have good oral bioavailability 
2-Molar Refractivity: between (40-130) is used as measurement of 
the real volume of the molecule and it is also related to the forces, 
which govern the ligand-receptor interactions [70]. 
The 10 high ranked lead molecules were prioritized to follow 
Lipinski’s rules of five, veber rule and molar refractivity [71] based 
on the drug likeliness properties are listed in table 5. 
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 Value to be 500< 5<  5< 10< =10< 140 =<  40-
130 
Casticin C 15 H 10 O 5 270.24 2.37 2.27 3 5 1 91 69.85 
Tangeritin C16H12O7 316.26 1.70 1.99 4 7 2 120 78.11 
Tamarixetin C16H12O7 316.26 1.67 1.99 4 7 2 120 78.11 
Malvidin C15H12O6 288.25 1.84 2.03 4 6 1 107 72.13 
Isorhamnetin C16H12O7 316.26 1.70 1.99 4 7 2 120 78.11 
Syringetin C 15 H 12 O 6 288.25 1.45 1.63 4 6 1 107 72.13 
Petunidin C21H22O9 254.24 2.49 2.56 2 4 1 71 67.97 
Tricin C16H14O6 302.28 1.93 1.94 3 6 2 96 76.93 
Fisetin C15H10O6 286.24 1.87 1.97 4 6 1 111 71.43 
Herbacetin C15H10O5 272.25 2.24 2.13 3 5 1 87 70.25 
Benzoic acid, 3-(benzoylamino)-2-
hydroxy 
C15H10O4 254.24 2.72 2.94 2 4 1 70 67.67 
1-calculated by ALOGPS 2.1 program http://www.vcclab.org/lab/alogps/start.html. 
2-Calculated by www. zinc. docking. o, https://pubchem.ncbi.nlm.nih.gov/search/search.cgi 
3-Calculated by ACD (Available Chemical Directory) 
*PSA: Polar Surface Area,*MW: Molecular weight, *HD: H bond donor, *HA: H bond acceptor. 
*RB: rotatable bonds. *MR: Molar refractivity 
#Octanol/Water partition coefficient 
 
CONCLUSION 
The results of the present study clearly demonstrated that the in 
silico molecular docking studies of selected flavonoids with FabF 
enzyme exhibited binding interactions and warranted further 
studies needed for the development of potent FabF inhibitors for the 
treatment of Pseudomonas aeruginosa. These results clearly 
indicated that casticinhas similar binding sites and interactions with 
FabF compared to the reference. 
These in silico studies are actually an added advantage to screen the 
FabF inhibition. Flavonoids may serve as useful leads in the 
development of clinically useful FabF inhibitors. Further, 
investigations on the above compound need in vitro and in vivo 
studies to develop potential chemical entities for the prevention and 
treatment of Pseudomonas aeruginosa infections. 
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